Tamsulosin HCI usp
Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
DOSAGE AND ADMINISTRATION:
0.4mg once daily for the treatment of the signs am symptoms of BPH. It should be administered approximately one half hour following the same meal each day. For those patients who fail to respond to the 0.4mg dose after two to four weeks of dosing, the dose of (Tamsulosin HCI) capsules can be increased to 0.8mg once daily.
With known hypersensitivity to tamsulosin HCI or any component of the product. With a history of orthostasis hypotension. Taking other alpha-adrenergic blocking agents. With severe hepatic insufficiency.
Warfarin and tamsulosin HCI.
At the first signs of orthostasis hypotension(dizziness weakness), the patient should sit or he down until 4he symptoms have disappeared. Before therapy with tamsulosin HCI is initiated, the patient should be examined in order to exclude the presence of other conditions which can cause the same symptoms as benign prostatic hyperplasia. Digital rectal examination a when necessary, determination of prostate specific antigen (PSA) should be performed before treatment and at regular interval and afterwards. Patients with end stage renal disease (creatinine clearance < 10m1 / min 1.73m2) should be approached with caution as these patients have not been studied. Patients should be advised about the possibility of priapism as a result of treatment with tamsulosin and other similar medications. Patients should be informed that this reaction is extremely rare, but if not brought to immediate medical attention, can lead to permanent erectile dysfunction (impotence). Intraoperative Floppy Iris Syndrome. (IFIS) has been observed during cataract surgery in some patients taking -Ae or who have previously been treated with alpha 1 adrenoceptor antagonists.
Only logged in customers who have purchased this product may leave a review.